RxDoctor Payments Data

Thomas Day, MD

Dermatology · Windsor Mill, MDNPI 1336112622

Payments from drug & device makers

$3,569in general payments, 2019–2025

Across 131 payments — averaging $27.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medimetriks Pharmaceuticals, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$476
  • Novartis$180
  • Incyte Corporation$173
  • E.r. Squibb & Sons, L.L.C.$157
  • Amgen$154
  • plus $898 from 18 others

What the payments were for

  • Consulting fees$1,20034%
  • Food & beverage$2,14660%
  • Education$2236%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,569 in reported general payments places this provider in the 55th percentile of 306 dermatology providers in Maryland.

See all dermatology providers in Maryland

Medicare billing

Part B allowed, 2024
$71,672
Medicare patients
264
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab111$414,417
Dupixent SyringeDupilumab24$89,643
Tacrolimus272$58,234
VtamaTapinarof12$16,218
Ciclopirox242$10,498
Fluocinolone AcetonideFluocinolone/Shower Cap179$10,024
Clobetasol Propionate81$6,251
Fluocinolone Acetonide73$5,153
Betamethasone Dipropionate78$4,350
Triamcinolone Acetonide236$2,956
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc21$2,938
Halobetasol Propionate30$2,828
Ammonium Lactate93$2,186
Fluocinonide35$1,817
Clindamycin Phosphate48$1,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dermavant Sciences, Inc.Vtama$44$16,21812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 306 dermatology providers in Maryland.

Other dermatology in Windsor Mill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →